liveBook · Manning

Pathway enrichment analysis

As explained in Build AI Drug Discovery Pipelines

Pathway enrichment analysis tests whether a set of genes is disproportionately represented in predefined biological pathways.

Pathway enrichment analysis tests whether dysregulated genes occur disproportionately in predefined biological pathways, helping connect molecular measurements to disease mechanisms. section 13.3.1

A practical target-discovery workflow uses it to:

  • Start with differential expression results from patient and control samples. section 13.3.1
  • Test which biological pathways are overrepresented among the dysregulated genes. section 13.3.1
  • Interpret disease-associated signatures such as ECM remodeling, epithelial-mesenchymal transition, and chronic inflammation. section 13.3.1

Idiopathic pulmonary fibrosis

In IPF, transcriptomic data from patient lung tissue were compared with age-matched controls. Enrichment analysis revealed signatures involving extracellular-matrix remodeling, epithelial-mesenchymal transition, and chronic inflammation, informing subsequent target analysis. section 13.3.1

Figure 13.7 The four stages of the rentosertib program. Multi-omics data and literature flow through PandaOmics to a scored target list; Chemistry42 generates and optimizes candidates against a multi-objective reward; experimental readouts feed back to refine the models; clinical development follows. Sections 13.3.1 through 13.3.4 walk through each stage.

Places pathway enrichment within a multimodal target-discovery pipeline that combines omics data and literature evidence before producing a scored target list. section 13.3.1

How Build AI Drug Discovery Pipelines covers it

How deep it goes
Explains pathway overrepresentation and interprets resulting signatures, without specifying statistical tests or implementation details.
Examples
Uses IPF gene-expression data to identify ECM remodeling, epithelial-mesenchymal transition, and chronic inflammation signatures.
What you can do after
Evaluate dysregulated gene lists by relating them to predefined disease-relevant biological pathways.
How it connects
Connects differential expression analysis with biological pathways, transcriptomics, network analysis, and target identification.

This explainer was generated by Manning's knowledge graph from the text of Build AI Drug Discovery Pipelines. The section links point to the parts of the book it draws on.